Exabis Library
Welcome to the e-CCO Library!
P480: Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P480: Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P480: Effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced diarrhoea/colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P480: Goals of treatment: preferences of inflammatory bowel disease patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P480: Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P481 Repeated surgery for recurrent ileocolonic Crohn’s disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P481: Effect of anti-TNFα therapy with daily physical activity in patients with Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P481: Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P481: Induction treatment with subcutaneous rather than intravenous ustekinumab is associated with comparable circulating drugs levels and early clinical response
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P481: profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P481: Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different “therapeutic window” between post-induction and maintenance treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P481: Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P482 Patient and physician perspectives on the management of inflammatory bowel disease: Disease remission and durability of treatment
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P482: Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitals
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P482: Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P482: Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P482: Safety and efficacy of ustekinumab for Crohn’s disease in the elderly population
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM